Search
telcagepant (MK-0974)
FDA approval pending (2009)
* On July 2011, Merck announced that it had discontinued development of telcagepan [2]
* Now FDA-approved? [3]
Indications:
- migraine
Dosage:
- 150 mg or 300 mg PO
Mechanism of action:
- calcitonin gene-related peptide receptor antagonist
- lacks vasoconstrictor effects of triptans
General
calcitonin gene-related peptide (CGRP) inhibitor
Database Correlations
PUBCHEM cid=11319053
References
- Ho TW et al,
Efficacy and tolerability of MK-0974 (telcagepant) a new oral
antagonist of calcitonin gene-related peptide receptor,
compared with zolmitriptan for acute migraine: A randomised,
placebo-controlled, parallel treatment trial.
Lancet 2008, 372:2115
PMID: 19036425
- Edvinsson L
CGRP-receptor antagonism in migraine treatment.
Lancet 2008, 372:2089
PMID: 19036426
- Wikipedia: Telcagepant
https://en.wikipedia.org/wiki/Telcagepant
- New Drug Approvals. Telcagepant Revisited. 2017
https://newdrugapprovals.org/2017/01/25/telcagepant-revisited/